drugset / Trial / NCT00163137

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

NCT00163137

Phase 3 Completed 540 enrolled Ligand Pharmaceuticals
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.

Timeline

Start
2003-05
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lasofoxifene Small molecule 0.25 mg
Comparator Raloxifene Other / unclassified 60 mg

Indications